Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
10x Genomics, Inc.
Report date July 29, 2022 · Filed August 25, 2022
Section 16 reporting ended · disclosed 2022-08-25. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 12, 2021 Filed Apr 13, 2021 16:40 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,302 | $182.75 | $237,937.77 |
DisclosureSEC source: 0001209191-21-026447 · doc4.xml · nonDerivative · entry 4 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,757 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $182.54 to $183.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 16:40 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,642 | $181.84 | $480,426.30 |
DisclosureSEC source: 0001209191-21-026447 · doc4.xml · nonDerivative · entry 3 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,059 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $181.39 to $182.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 16:40 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 907 | $181.10 | $164,260.33 |
DisclosureSEC source: 0001209191-21-026447 · doc4.xml · nonDerivative · entry 2 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,701 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $180.39 to $181.28. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 16:40 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 17,000 | $1.16 | $19,720.00 |
DisclosureSEC source: 0001209191-21-026447 · doc4.xml · nonDerivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,608 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| March 19, 2021 Filed May 26, 2021 20:25 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantStock Option (right to buy) · Derivative | 22,338 | $0.00 Strike: $177.76 | $0.00 |
DisclosureSEC source: 0001209191-21-036100 · doc4.xml · derivative · entry 3 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,338 Underlying: Class A Common Stock · 22,338 shares Expires 2031-03-19 F5 · derivative.exercise_date: This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one forty-eighth of the shares on May 1, 2021 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| March 19, 2021 Filed May 26, 2021 20:25 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 8,935 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-036100 · doc4.xml · nonDerivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,543 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock. One-sixteenth of the RSUs shall vest on May 21, 2021 and on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. F2 · balance_after: The number of shares beneficially owned following the reported transaction is as of March 19, 2021. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 16:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001209191-21-020871 · doc4.xml · derivative · entry 8 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 579,000 Underlying: Class A Common Stock · 17,000 shares Expires 2027-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · derivative.exercise_date: This option, originally for 800,000 shares, of which 221,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 16:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,100 | $159.51 | $334,976.88 |
DisclosureSEC source: 0001209191-21-020871 · doc4.xml · nonDerivative · entry 7 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,608 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $159.23 to $159.88. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 16:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,176 | $158.85 | $504,513.00 |
DisclosureSEC source: 0001209191-21-020871 · doc4.xml · nonDerivative · entry 6 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,708 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $158.23 to $159.21. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 16:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,211 | $157.70 | $348,683.54 |
DisclosureSEC source: 0001209191-21-020871 · doc4.xml · nonDerivative · entry 5 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,884 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $157.11 to $158.10. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 16:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,606 | $156.52 | $564,404.27 |
DisclosureSEC source: 0001209191-21-020871 · doc4.xml · nonDerivative · entry 4 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,095 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $156.09 to $157.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 16:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,807 | $155.54 | $592,148.39 |
DisclosureSEC source: 0001209191-21-020871 · doc4.xml · nonDerivative · entry 3 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,701 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $155.01 to $156.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 16:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,100 | $154.52 | $324,491.58 |
DisclosureSEC source: 0001209191-21-020871 · doc4.xml · nonDerivative · entry 2 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,508 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $154.01 to $154.89. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 16:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 17,000 | $1.16 | $19,720.00 |
DisclosureSEC source: 0001209191-21-020871 · doc4.xml · nonDerivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,608 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 20:06 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001209191-21-007557 · doc4.xml · derivative · entry 8 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 596,000 Underlying: Class A Common Stock · 17,000 shares Expires 2027-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · derivative.exercise_date: This option, originally for 800,000 shares, of which 204,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 20:06 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 200 | $178.92 | $35,783.00 |
DisclosureSEC source: 0001209191-21-007557 · doc4.xml · nonDerivative · entry 7 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,608 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $178.86 to $178.97. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 20:06 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 900 | $177.86 | $160,073.46 |
DisclosureSEC source: 0001209191-21-007557 · doc4.xml · nonDerivative · entry 6 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,808 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $177.67 to $178.24. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 20:06 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,700 | $176.94 | $477,751.23 |
DisclosureSEC source: 0001209191-21-007557 · doc4.xml · nonDerivative · entry 5 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,708 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $176.53 to $177.36. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 20:06 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 8,451 | $175.94 | $1,486,839.36 |
DisclosureSEC source: 0001209191-21-007557 · doc4.xml · nonDerivative · entry 4 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,408 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $175.50 to $176.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 20:06 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,003 | $175.25 | $701,522.15 |
DisclosureSEC source: 0001209191-21-007557 · doc4.xml · nonDerivative · entry 3 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,859 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $174.50 to $175.49. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 20:06 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 746 | $173.99 | $129,796.24 |
DisclosureSEC source: 0001209191-21-007557 · doc4.xml · nonDerivative · entry 2 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,862 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $173.45 to $174.44. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 20:06 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 17,000 | $1.16 | $19,720.00 |
DisclosureSEC source: 0001209191-21-007557 · doc4.xml · nonDerivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,608 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 17:12 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001209191-21-002188 · doc4.xml · derivative · entry 6 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 613,000 Underlying: Class A Common Stock · 17,000 shares Expires 2027-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · derivative.exercise_date: This option, originally for 800,000 shares, of which 187,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 17:12 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 400 | $141.77 | $56,708.00 |
DisclosureSEC source: 0001209191-21-002188 · doc4.xml · nonDerivative · entry 5 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,608 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $141.40 to $142.07. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 17:12 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,135 | $140.74 | $441,211.12 |
DisclosureSEC source: 0001209191-21-002188 · doc4.xml · nonDerivative · entry 4 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,008 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $140.34 to $141.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 17:12 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 10,465 | $139.89 | $1,463,946.76 |
DisclosureSEC source: 0001209191-21-002188 · doc4.xml · nonDerivative · entry 3 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,143 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $139.34 to $140.33. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 17:12 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,000 | $138.97 | $416,907.60 |
DisclosureSEC source: 0001209191-21-002188 · doc4.xml · nonDerivative · entry 2 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,608 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $138.33 to $139.32. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 17:12 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 17,000 | $1.16 | $19,720.00 |
DisclosureSEC source: 0001209191-21-002188 · doc4.xml · nonDerivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,608 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 17:11 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 13,333 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-20-065545 · doc4.xml · derivative · entry 4 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,667 Underlying: Class A Common Stock · 13,333 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option, originally for 125,000 shares, of which 13,333 shares have been exercised, vested as to one forty-eighth of the shares on October 1, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 17:11 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 20,312 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001209191-20-065545 · doc4.xml · derivative · entry 3 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,688 Underlying: Class A Common Stock · 20,312 shares Expires 2027-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option, originally for 25,000 shares, of which 20,312 shares have been exercised, vested as to one forty-eighth of the shares on October 1, 2017 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 17:11 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 13,333 | $5.04 | $67,198.32 |
DisclosureSEC source: 0001209191-20-065545 · doc4.xml · nonDerivative · entry 2 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,608 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 17:11 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 20,312 | $1.20 | $24,374.40 |
DisclosureSEC source: 0001209191-20-065545 · doc4.xml · nonDerivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 20:32 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001209191-20-061711 · doc4.xml · derivative · entry 7 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 630,000 Underlying: Class A Common Stock · 17,000 shares Expires 2027-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · derivative.exercise_date: This option, originally for 800,000 shares, of which 170,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 20:32 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,718 | $153.58 | $263,852.16 |
DisclosureSEC source: 0001209191-20-061711 · doc4.xml · nonDerivative · entry 6 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 963 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $153.39 to $154.08. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 20:32 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,410 | $152.96 | $368,628.06 |
DisclosureSEC source: 0001209191-20-061711 · doc4.xml · nonDerivative · entry 5 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,681 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $152.36 to $153.34. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 20:32 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,295 | $151.68 | $348,096.42 |
DisclosureSEC source: 0001209191-20-061711 · doc4.xml · nonDerivative · entry 4 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,091 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $151.36 to $152.24. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 20:32 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,496 | $150.87 | $829,161.18 |
DisclosureSEC source: 0001209191-20-061711 · doc4.xml · nonDerivative · entry 3 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,386 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $150.36 to $151.35. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 20:32 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,081 | $150.02 | $762,244.51 |
DisclosureSEC source: 0001209191-20-061711 · doc4.xml · nonDerivative · entry 2 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,882 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $149.36 to $150.35. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 20:32 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 17,000 | $1.16 | $19,720.00 |
DisclosureSEC source: 0001209191-20-061711 · doc4.xml · nonDerivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 21:33 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 6,496 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001209191-20-057066 · doc4.xml · derivative · entry 13 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 647,000 Underlying: Class A Common Stock · 6,496 shares Expires 2027-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F12 · derivative.exercise_date: This option, originally for 800,000 shares, of which 153,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 21:33 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 200 | $138.43 | $27,686.00 |
DisclosureSEC source: 0001209191-20-057066 · doc4.xml · nonDerivative · entry 11 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 963 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F10 · price: This transaction was executed in multiple trades at prices ranging from $138.20 to $138.66. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 21:33 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,898 | $137.56 | $536,202.64 |
DisclosureSEC source: 0001209191-20-057066 · doc4.xml · nonDerivative · entry 10 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,163 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F9 · price: This transaction was executed in multiple trades at prices ranging from $137.11 to $138.04. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 21:33 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,198 | $136.60 | $300,254.71 |
DisclosureSEC source: 0001209191-20-057066 · doc4.xml · nonDerivative · entry 9 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,061 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · price: This transaction was executed in multiple trades at prices ranging from $136.09 to $137.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 21:33 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 200 | $135.42 | $27,084.00 |
DisclosureSEC source: 0001209191-20-057066 · doc4.xml · nonDerivative · entry 8 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,259 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $135.09 to $135.75. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 21:33 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 6,496 | $1.16 | $7,535.36 |
DisclosureSEC source: 0001209191-20-057066 · doc4.xml · nonDerivative · entry 7 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 21:33 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 10,504 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001209191-20-057066 · doc4.xml · derivative · entry 12 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 653,496 Underlying: Class A Common Stock · 10,504 shares Expires 2027-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F11 · derivative.exercise_date: This option, originally for 800,000 shares, of which 146,504 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 21:33 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 400 | $139.25 | $55,698.00 |
DisclosureSEC source: 0001209191-20-057066 · doc4.xml · nonDerivative · entry 6 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 963 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $139.23 to $139.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 21:33 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 800 | $138.40 | $110,719.04 |
DisclosureSEC source: 0001209191-20-057066 · doc4.xml · nonDerivative · entry 5 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,363 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $138.00 to $138.81. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 21:33 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,200 | $136.97 | $164,360.64 |
DisclosureSEC source: 0001209191-20-057066 · doc4.xml · nonDerivative · entry 4 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,163 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $136.65 to $137.42. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 21:33 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 6,604 | $136.06 | $898,571.94 |
DisclosureSEC source: 0001209191-20-057066 · doc4.xml · nonDerivative · entry 3 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,363 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $135.65 to $136.63. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.